Company intelligence / Profile preview

RFS Pharma

Tucker, Georgia, United Statesmarketscreener.com ↗

Ownership: Private
Employees: ~50
Development stage: Phase 2

Overview

RFS Pharma developed antiviral agents with a focus on small molecule nucleoside analogs. Its lead program, amdoxovir for HIV, reached advanced Phase 2 clinical studies. The company also had preclinical programs for hepatitis and norovirus infections. In November 2014, it was acquired by Cocrystal Pharma in a $178 million deal to combine their antiviral drug development platforms and pipelines.[6][1][3]

Therapeutic areas: Infectious Diseases
Modalities: Small molecules (notably nucleoside analogs)[1][5]
Industry: Biotech

Drug pipeline

2 assets

PSI-6130

Phase 2

Indications: Hepatitis C virus infection

1 more asset in the full pipeline.

Request access →

Partnerships

Genoscience Pharma—joint venture for viral disease drug development in HCV area[5].

Beyond the preview

Go deeper on RFS Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RFS Pharma.

Explore the full profile